Edesa Biotech

EDSA

Biotechnology · Healthcare

Price

$4.43

-0.33 (-6.93%)

Market Cap

$42.7M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+229.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.7M (2021) → 5.7M (2025)

Winston Score History

The full picture

Edesa Biotech is a small clinical-stage biotechnology company focused on developing drugs to treat inflammatory and immune-related skin conditions. Its lead programs target conditions like atopic dermatitis (eczema) and hypertrophic scars, with potential customers being patients and healthcare providers in dermatology. The company does not yet sell any approved products and is still running clinical trials to test whether its experimental medicines are safe and effective.

Edesa earns no product revenue right now, relying instead on cash reserves and periodic financing to fund its research and development operations. It is headquartered in Canada and operates primarily in North America, with a very small team typical of early-stage biotech firms. The company's main risk is that it must successfully advance its drug candidates through clinical trials and secure regulatory approval before it can generate any sales — a process that is expensive, uncertain, and could require additional fundraising that dilutes existing shareholders.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-140.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$4M/ year

↑ Rising (+27% vs prior year)

R&D investment increasing — building for the future

Insider Activity

20.3%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~10 months

$10M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Edesa Biotech has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-166.0%

Weak — -166.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial